☆ 4.8 Editorial Material

Anti-Tau Antibodies: Hitting the Target

NEURON (2013)

Journal

NEURON

Volume 80, Issue 2, Pages 254-256

Publisher

CELL PRESS

DOI: 10.1016/j.neuron.2013.10.009

Keywords

-

Categories

Neurosciences

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Immunotherapies targeting tau in mouse models of human tauopathies could have disease-modifying effects. In this issue of Neuron, Yanamandra et al. (2013) use tau antibodies, which effectively block tau seeding in culture, to attenuate tauopathy and improve cognition in mutant tau mouse models.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Chemistry, Analytical

Nanozymes-Hitting the Biosensing Target

Yingfen Wu, Diane C. Darland, Julia Xiaojun Zhao

Summary: Nanozymes are artificial enzymes with excellent catalytic activities, adaptable surface structures, and three main classes that catalyze specific reactions. They have expanded applications in diverse fields, with biosensing being the most popular. Nanozyme-based novel biosensors have been designed to detect various substances like ions, small molecules, nucleic acids, proteins, and cancer cells.

SENSORS (2021)

Add to Collection

Article Neurosciences

Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid

Dina Rodrigues Martins, Marc Vandermeeren, Kristof Van Kolen, Eddy Brepoels, Marianne Borgers, Cindy Wintmolders, Charlotte Delay, Astrid Bottelbergs, Marc Mercken, Clara Theunis

Summary: Researchers developed specific antibodies to detect mouse tau protein, which showed high specificity and can be used to detect tau in mouse brain homogenate and cerebrospinal fluid, as well as to detect aggregation of endogenous mouse tau. These antibodies are important tools to interpret results from different model systems and study the role of endogenous tau in tau aggregation and pathology observed in diverse mouse models.

JOURNAL OF ALZHEIMERS DISEASE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients

Ioanna Tsantzali, Fotini Boufidou, Eleni Sideri, Antonis Mavromatos, Myrto G. Papaioannou, Aikaterini Foska, Ioannis Tollos, Sotirios G. Paraskevas, Anastasios Bonakis, Konstantinos I. Voumvourakis, Georgios Tsivgoulis, Elisabeth Kapaki, George P. Paraskevas

Summary: Analysis of classical cerebrospinal fluid biomarkers, especially in the context of a diagnostic system like AT(N), can be a significant tool for diagnosing Alzheimer's disease accurately during a patient's lifetime. Despite atypical clinical presentations, the classical biomarker profile was consistent with Alzheimer's disease in four patients, demonstrating the potential usefulness of these biomarkers for identifying the biochemical fingerprints of the disease.

BIOMEDICINES (2021)

Add to Collection

Article Business, Finance

Hitting the elusive inflation target

Francesco Bianchi, Leonardo Melosi, Matthias Rottner

Summary: The article suggests an asymmetric monetary policy rule that corrects the deflationary bias by responding less aggressively to inflation above the target rate, which can effectively improve welfare and reduce the risk of deflationary spirals.

JOURNAL OF MONETARY ECONOMICS (2021)

Add to Collection

Review Neurosciences

To target Tau pathologies, we must embrace and reconstruct their complexities

Galina Limorenko, Hilal A. Lashuel

Summary: The study explores the effects of heparin on Tau aggregation and provides new insights into its role in Tauopathies. The review calls for a reassessment of approaches to studying Tau aggregation mechanisms, development of better diagnostic tools to enhance understanding of Tauopathies, and more effective means for drug development.

NEUROBIOLOGY OF DISEASE (2021)

Add to Collection

Article Computer Science, Artificial Intelligence

Hitting the target: stopping active learning at the cost-based optimum

Zac Pullar-Strecker, Katharina Dost, Eibe Frank, Joerg Wicker

Summary: This research provides a large-scale comparison of stopping criteria for pool-based active learning, offering actionable recommendations for practitioners to choose the most suitable criterion for their domain and reduce labeling costs.

MACHINE LEARNING (2022)

Add to Collection

Article Multidisciplinary Sciences

ATP1A3 as a target for isolating neuron-specific extracellular vesicles from human brain and biofluids

Yang You, Zhengrong Zhang, Nadia Sultana, Maria Ericsson, Yuka A. Martens, Min Sun, Takahisa Kanekiyo, Seiko Ikezu, Scott A. Shaffer, Tsuneya Ikezu

Summary: This study demonstrates that ATP1A3 is a reliable biomarker for neuron-derived extracellular vesicles (NDEVs) and shows higher enrichment of cargo proteins relevant to Alzheimer's disease. It suggests that ATP1A3 can be used as a diagnostic target for neurological diseases.

SCIENCE ADVANCES (2023)

Add to Collection

Review Medicine, General & Internal

Autoimmune Encephalitis with Antibodies: Anti-NMDAR, Anti-AMPAR, Anti-GQ1b, Anti-DPPX, Anti-CASPR2, Anti-LGI1, Anti-RI, Anti-Yo, Anti-Hu, Anti-CV2 and Anti-GABAAR, in the Course of Psychoses, Neoplastic Diseases, and Paraneoplastic Syndromes

Michal Braczkowski, Dariusz Soszynski, Alicja Sierakowska, Ryszard Braczkowski, Klaudia Kufel, Beata Labuz-Roszak

Summary: Encephalitis is a complex condition with various causes and symptoms. Autoimmune encephalitis, which accounts for about 4% of encephalitis cases, is caused by autoantibodies attacking the central nervous system. This paper discusses the mental and neurological symptoms of autoimmune encephalitis, as well as the coexistence with psychosis and neoplastic diseases. Early diagnosis and targeted treatment are emphasized for a successful therapeutic process. The research methodology involved searching for articles from 2007 to 2023 using search engines like PubMed and Medline.

DIAGNOSTICS (2023)

Add to Collection

Editorial Material Chemistry, Multidisciplinary

Hitting the buffers

Bruce C. Gibb

Summary: Buffers are not just innocuous substances for pH regulation, they can also interact with biomacromolecules.

NATURE CHEMISTRY (2021)

Add to Collection

News Item Biochemistry & Molecular Biology

Hitting the hotspots

Christopher B. Marshall, Mitsuhiko Ikura

Summary: This study demonstrates that optimizing non-covalent interactions with a cryptic pocket can significantly enhance the potency for another hotspot mutation.

NATURE CHEMICAL BIOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Multicomponent Petasis reaction for the identification of pyrazine based multi-target directed anti-Alzheimer?s agents: In-silico design, synthesis, and characterization

Hari Madhav, Somaya A. Abdel-Rahman, Md Amiruddin Hashmi, Md Ataur Rahman, Mohammad Rehan, Kavita Pal, Shahid M. Nayeem, Moustafa T. Gabr, Nasimul Hoda

Summary: The study developed pyrazine-based multi-target directed ligands (MTDLs) through multicomponent Petasis reaction for the simultaneous inhibition of tau-aggregation and human acetylcholinesterase (hAChE) in Alzheimer's disease. The synthesized ligands were structurally validated, and showed strong inhibitory effects against tau-oligomerization and hAChE, with moderate activity against A beta 42. Compound 21 exhibited potential neuroprotective effects and displayed higher binding energy with AChE compared to compound 24. This study provides insights into the design of new MTDLs and identifies compound 21 as a potential obstacle in the development of anti-AD medications.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Add to Collection

Article Physics, Fluids & Plasmas

Distribution of the span of one-dimensional confined random processes before hitting a target

J. Klinger, R. Voituriez, O. Benichou

Summary: This study examines the distribution of the number of distinct sites visited by a random walker before hitting a target site in a finite one-dimensional domain, expressed in terms of splitting probabilities. Explicit results are provided for classical random processes such as simple symmetric random walks and biased random walks. Additionally, extensions to reflecting boundary conditions and continuous processes are discussed.

PHYSICAL REVIEW E (2021)

Add to Collection

Review Clinical Neurology

mTOR (Mammalian Target of Rapamycin): Hitting the Bull's Eye for Enhancing Neurogenesis After Cerebral Ischemia?

Jiale Gao, Mingjiang Yao, Dennis Chang, Jianxun Liu

Summary: Ischemic stroke is a leading cause of morbidity and disability globally. The body's limited repair capacity makes the sequelae of serious neurological damage irreversible. However, endogenous neurogenesis induced by cerebral ischemia plays a critical role in the repair and regeneration of impaired neural cells after ischemic brain injury.

STROKE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope

Arthur S. Kim, Natasha M. Kafai, Emma S. Winkler, Theron C. Jr Jr Gilliland, Emily L. Cottle, James T. Earnest, Prashant N. Jethva, Paulina Kaplonek, Aadit P. Shah, Rachel H. Fong, Edgar Davidson, Ryan J. Malonis, Jose A. Quiroz, Lauren E. Williamson, Lo Vang, Matthias Mack, James E. Jr Jr Crowe, Benjamin J. Doranz, Jonathan R. Lai, Galit Alter, Michael L. Gross, William B. Klimstra, Daved H. Fremont, Michael S. Diamond

Summary: Two poorly neutralizing human monoclonal antibodies, DC2.112 and DC2.315, have been identified as pan-protective against both arthritogenic and encephalitic alphaviruses. These antibodies target a conserved epitope in the E1 protein domain II and offer protection through multiple mechanisms, including inhibiting viral egress and monocyte-dependent Fc effector functions. This finding provides potential targets for pan-alphavirus immunotherapy and vaccine design.

CELL (2021)

Add to Collection

Review Oncology

Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma

Dannel Yeo, Laura Castelletti, Nico van Zandwijk, John E. J. Rasko

Summary: Mesothelioma is a deadly cancer with limited treatment options. Mesothelin is overexpressed in mesothelioma but not in normal cells, making it a potential biomarker and therapeutic target. Research on the diagnostic and therapeutic value of mesothelin in mesothelioma patients is ongoing to improve patient outcomes.

CANCERS (2021)

Add to Collection

Article Neurosciences

Statistically Defined Parkinson's Disease Executive and Memory Cognitive Phenotypes: Demographic, Behavioral, and Structural Neuroimaging Comparisons

Samuel J. Crowley, Guita Banan, Manish Amin, Jared J. Tanner, Loren Hizel, Peter Nguyen, Babette Brumback, Katie Rodriguez, Nikolaus McFarland, Dawn Bowers, Mingzhou Ding, Thomas A. Mareci, Catherine C. Price

Summary: This study aimed to statistically derive PD executive and memory phenotypes, comparing them on various disease and demographic variables, vascular risk factors, and specific neuroimaging variables related to executive and memory function. The clusters identified different structural gray and white matter patterns, with PD Executive showing less subcortical gray matter and white matter compared to PD Memory and PD Cognitively Well. These findings provide insights into phenotypic demographics, cognitive patterns, and structural brain profiles in individuals with PD.

JOURNAL OF PARKINSONS DISEASE (2021)

Add to Collection

Article Neurosciences

The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism

Caroline M. Tanner, Steven R. Cummings, Michael A. Schwarzschild, Ethan G. Brown, E. Ray Dorsey, Alberto J. Espay, Nicholas B. Galifianakis, Samuel M. Goldman, Irene Litvan, Nijee Luthra, Nikolaus R. McFarland, Kyle T. Mitchell, David G. Standaert, Douglas C. Bauer, Susan L. Greenspan, James C. Beck, Kenneth W. Lyles

Summary: TOPAZ is a clinical trial testing the efficacy of zoledronic acid for fracture prevention in patients with Parkinson's disease, with a unique home-based design to enhance feasibility and convenience for participants.

NPJ PARKINSONS DISEASE (2021)

Add to Collection

Article Neurosciences

Robust α-synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy

Ethan W. Hass, Zachary A. Sorrentino, Grace M. Lloyd, Nikolaus R. McFarland, Stefan Prokop, Benoit I. Giasson

Summary: Multiple system atrophy (MSA) is a neurodegenerative disease characterized by the accumulation of glial cytoplasmic inclusions (GCIs). Research has shown that MSA patients have abundant neuronal alpha Syn pathology in specific regions of the brain, which differs from GCIs and may play a role in driving the pathogenesis of MSA.

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)

Add to Collection

Review Clinical Neurology

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Brent Bluett, Alexander Y. Pantelyat, Irene Litvan, Farwa Ali, Diana Apetauerova, Danny Bega, Lisa Bloom, James Bower, Adam L. Boxer, Marian L. Dale, Rohit Dhall, Antoine Duquette, Hubert H. Fernandez, Jori E. Fleisher, Murray Grossman, Michael Howell, Diana R. Kerwin, Julie Leegwater-Kim, Christiane Lepage, Peter Alexander Ljubenkov, Martina Mancini, Nikolaus R. McFarland, Paolo Moretti, Erica Myrick, Pritika Patel, Laura S. Plummer, Federico Rodriguez-Porcel, Julio Rojas, Christos Sidiropoulos, Miriam Sklerov, Leonard L. Sokol, Paul J. Tuite, Lawren VandeVrede, Jennifer Wilhelm, Anne-Marie A. Wills, Tao Xie, Lawrence Golbe

Summary: PSP and CBS are tauopathies with relentless progression, starting in the mid-60s and leading to death in about 7 years. Clinical deficits are diverse and include rigidity, bradykinesia, gait freezing, dystonia, apraxia, and cognitive dysfunction. CurePSP Centers of Care network was established in 2017 in North America to improve patient access to expertise and collaboration in managing these disorders.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline

David J. Arpin, Trina Mitchell, Derek B. Archer, Roxana G. Burciu, Winston T. Chu, Hanzhi Gao, Thomas Guttuso, Christopher W. Hess, Song Lai, Irene A. Malaty, Nikolaus R. McFarland, Ofer Pasternak, Catherine C. Price, Aparna Wagle Shukla, Samuel S. Wu, Michael S. Okun, David E. Vaillancourt

Summary: The study did not find evidence that 1mg/day of rasagiline has a disease-modifying effect in Parkinson's Disease over 1 year. The free-water accumulation in pSN increased significantly over 1 year, and baseline free-water levels were related to clinical motor progression.

MOVEMENT DISORDERS (2022)

Add to Collection

Article Clinical Neurology

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease

Andrea Quattrone, Maria G. Bianco, Angelo Antonini, David E. Vaillancourt, Klaus Seppi, Roberto Ceravolo, Antonio P. Strafella, Gioacchino Tedeschi, Alessandro Tessitore, Roberto Cilia, Maurizio Morelli, Salvatore Nigro, Basilio Vescio, Pier Paolo Arcuri, Rosa De Micco, Mario Cirillo, Luca Weis, Eleonora Fiorenzato, Roberta Biundo, Roxana G. Burciu, Florian Krismer, Nikolaus R. McFarland, Christoph Mueller, Elke R. Gizewski, Mirco Cosottini, Eleonora Del Prete, Sonia Mazzucchi, Aldo Quattrone

Summary: This study developed an automated Magnetic Resonance Parkinsonism Index 2.0 (MRPI 2.0) algorithm to differentiate progressive supranuclear palsy-parkinsonism (PSP-P) from Parkinson's disease (PD) and validated its diagnostic performance in two large independent cohorts. The automated MRPI 2.0 showed excellent performance in distinguishing PSP-P from PD and control subjects in both cohorts, suggesting its generalizability. The use of the automated MRPI 2.0 algorithm could standardize measures in patients with PSP-P across centers and have a positive impact on multicenter studies and clinical trials.

MOVEMENT DISORDERS (2022)

Add to Collection

Letter Clinical Neurology

Recommendations for Virtual Administration of the PSP Rating Scale

Anne-Marie Wills, Lawrence I. Golbe, Anthony E. Lang, Tao Xie, Marian L. Dale, Alberto Espay, Maria Carmela Tartaglia, Susan H. Fox, Sotirios Andreas Parashos, Nikolaus R. McFarland, Ruth B. Schneider, Federico Rodriguez-Porcel, Steven A. Gunzler, Alexander Pantelyat

MOVEMENT DISORDERS (2022)

Add to Collection

Article Neurosciences

WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes

Rebecca L. Wallings, Laura P. Hughes, Hannah A. Staley, Zachary D. Simon, Nikolaus R. McFarland, Roy N. Alcalay, Alicia Garrido, Maria Jose Marti, Eduardo Tolosa Sarro, Nicolas Dzamko, Malu Gamez Tansey

Summary: Both LRRK2 and GCase are potential targets for Parkinson's disease treatment, and their involvement in lysosome-related pathways has been suggested. This study developed a standardized protocol called WHOPPA using flow cytometry assays to measure LRRK2 and GCase activities in immune cells. The results showed increased LRRK2 levels and activity, decreased GCase index, and increased cytokine release in PD patient samples. The study also demonstrated a positive correlation between LRRK2 levels and the expression of pRab10 and HLA-DR in classical monocytes. This protocol could be used as a reliable and reproducible biomarker assay in larger cohorts of PD patients.

FRONTIERS IN CELLULAR NEUROSCIENCE (2022)

Add to Collection

Correction Biochemistry & Molecular Biology

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial (August, 10.1038/s41591-021-01455-x, 2021)

Tien Dam, Adam L. Boxer, Lawrence I. Golbe, Gunter U. Hoglinger, Huw R. Morris, Irene Litvan, Anthony E. Lang, Jean-Christophe Corvol, Ikuko Aiba, Michael Grundman, Lili Yang, Beth Tidemann-Miller, Joseph Kupferman, Kristine Harper, Kubra Kamisoglu, Michael J. Wald, Danielle L. Graham, Liz Gedney, John O'Gorman, Samantha Budd Haeberlein, Ikuko Aiba, Angelo Antonini, Diana Apetauerova, Jean-Philippe Azulay, Ernest Balaguer Martinez, Jee Bang, Paolo Barone, Matthew Barrett, Danny Bega, Daniela Berg, Koldo Berganzo Corrales, Yvette Bordelon, Adam L. Boxer, Moritz Brandt, Norbert Brueggemann, Giovanni Castelnovo, Roberto Ceravolo, Rosalind Chuang, Sun Ju Chung, Alistair Church, Jean-Christophe Corvol, Paola Cudia, Marian Dale, Luc Defebvre, Sophie Drapier, Erika D. Driver-Dunckley, Georg Ebersbach, Karla M. Eggert, Aaron Ellenbogen, Alexandre Eusebio, Andrew H. Evans, Natalia Fedorova, Elizabeth Finger, Alexandra Foubert-Samier, Boyd Ghosh, Lawrence Golbe, Francisco Grandas Perez, Murray Grossman, Deborah Hall, Kyoko Hamada, Kazuko Hasegawa, Guenter Hoeglinger, Lawrence Honig, David Houghton, Xuemei Huang, Stuart Isaacson, SeongBeom Koh, Jaime Kulisevsky Bojarski, Anthony E. Lang, Peter Nigel Leigh, Irene Litvan, Juan Jose Lopez Lozano, Jose Luis Lopez-Sendon Moreno, Albert Christian Ludolph, Ma Rosario Luquin Piudo, Irene Martinez Torres, Nikolaus McFarland, Wassilios Meissner, Tiago Mestre, Pablo Mir Rivera, Eric Molho, Britt Mollenhauer, Huw R. Morris, Miho Murata, Tomokazu Obi, Fabienne Ory Magne, Padraig O'Suilleabhain, Rajesh Pahwa, Alexander Pantelyat, Nicola Pavese, Dmitry Pokhabov, Johannes Prudlo, Federico Rodriguez-Porcel, James Rowe, Joseph Savitt, Alfons Schnitzler, Joerg B. Schulz, Klaus Seppi, Binit Shah, Holly Shill, David Shprecher, Maria Stamelou, Malcolm Steiger, Yuji Takahashi, Hiroshi Takigawa, Carmela Tartaglia, Lars Toenges, Daniel Truong, Winona Tse, Paul Tuite, Dieter Volc, Anne-Marie A. Wills, Dirk Woitalla, Tao Xie, Tatsuhiko Yuasa, Sarah Elizabeth Zauber, Theresa Zesiewicz

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, Research & Experimental

Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial

Charity G. Patterson, Elizabeth Joslin, Alexandra B. Gil, Wendy Spigle, Todd Nemet, Lana Chahine, Cory L. Christiansen, Ed Melanson, Wendy M. Kohrt, Martina Mancini, Deborah Josbeno, Katherine Balfany, Garett Griffith, Mac Kenzie Dunlap, Guillaume Lamotte, Erin Suttman, Danielle Larson, Chantale Branson, Kathleen E. McKee, Li Goelz, Cynthia Poon, Barbara Tilley, Un Jung Kang, Malu Gamez Tansey, Nijee Luthra, Caroline M. Tanner, Jacob M. Haus, Giamila Fantuzzi, Nikolaus R. McFarland, Paulina Gonzalez-Latapi, Tatiana Foroud, Robert Motl, Michael A. Schwarzschild, Tanya Simuni, Kenneth Marek, Anna Naito, Codrin Lungu, Daniel M. Corcos

Summary: This article introduces a research study on the effects of high-intensity endurance exercise on the progression of Parkinson's disease. The study aims to explore whether high-intensity endurance training can slow down the progression of the disease, thus improving the quality of life for patients.

TRIALS (2022)

Add to Collection

Article Neurosciences

Distinct cortical and subcortical predictors of Purdue Pegboard decline in Parkinson's disease and atypical parkinsonism

Bradley J. Wilkes, Emily R. Tobin, David J. Arpin, Wei-en Wang, Michael S. Okun, Michael S. Jaffee, Nikolaus R. McFarland, Daniel M. Corcos, David E. Vaillancourt

Summary: Objective measures of disease progression using the Purdue Pegboard Test (PPT) were conducted in patients with Parkinson's disease (PD), atypical Parkinsonism, and healthy controls. The decline in PPT performance in PD patients correlated with motor symptom progression, while no such decline was seen in controls. Neuroimaging measures from the basal ganglia were significant predictors of PPT performance in PD, and cortical, basal ganglia, and cerebellar regions were predictors for atypical Parkinsonism. Accelerometry in PD patients showed diminished acceleration range and irregular patterns, which correlated with PPT scores.

NPJ PARKINSONS DISEASE (2023)

Add to Collection

Meeting Abstract Clinical Neurology

Enhancing Pandemic-Sensitive Recruitment Strategies for a Remote, Randomized Placebo-Controlled Trial for Fracture Prevention in Patients with Neurodegenerative Parkinsonisms (P1-1.Virtual)

Nijee Luthra, Ethan Brown, Samuel Goldman, Rafael Zuzuarregui, Trisha Hue, Christopher Schambach, Ian Bledsoe, Michael Schwarzschild, E. Ray Dorsey, Alberto Espay, Irene Litvan, Nikolaus McFarland, Kyle Mitchell, David Standaert, James Beck, Helen Rowbotham, Cheryl Meng, Jacque Perkins, Primi Ranola, Raymundo Picos, Dana Kriesel, Kenneth Lyles, Steve Cummings, Caroline Tanner

NEUROLOGY (2022)

Add to Collection

Article Neuroimaging

Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

Trina Mitchell, Bradley J. Wilkes, Derek B. Archer, Winston T. Chu, Stephen A. Coombes, Song Lai, Nikolaus R. McFarland, Michael S. Okun, Mieniecia L. Black, Ellen Herschel, Tanya Simuni, Cynthia Comella, Mitra Afshari, Tao Xie, Hong Li, Todd B. Parrish, Ajay S. Kurani, Daniel M. Corcos, David E. Vaillancourt

Summary: Advanced diffusion imaging techniques can detect longitudinal changes in atypical Parkinsonian syndromes. The study found that MSAp and PSP had more declines in descending sensorimotor tracts compared to PD. PSP also showed longitudinal impairments in multiple transcallosal tracts, while MSAp and PD did not. Additionally, there were longitudinal changes in gray matter regions that had previously shown impairments in MSAp and PSP.

NEUROIMAGE-CLINICAL (2022)

Add to Collection

Meeting Abstract Hospitality, Leisure, Sport & Tourism

Longitudinal Decline in Purdue Pegboard Performance in Parkinson's Disease

Emily R. Tobin, Bradely J. Wilkes, David J. Arpin, Michael S. Okun, Michael S. Jaffee, Nikolaus R. McFarland, Daniel M. Corcos, David E. Vaillancourt

JOURNAL OF SPORT & EXERCISE PSYCHOLOGY (2022)

Add to Collection

Article Clinical Neurology

A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study

Andrea Quattrone, Angelo Antonini, David E. Vaillancourt, Klaus Seppi, Roberto Ceravolo, Antonio P. Strafella, Maurizio Morelli, Salvatore Nigro, Basilio Vescio, Maria G. Bianco, Roberta Vasta, Pier Paolo Arcuri, Luca Weis, Eleonora Fiorenzato, Roberta Biundo, Roxana G. Burciu, Florian Krismer, Nikolaus R. McFarland, Christoph Mueller, Elke R. Gizewski, Mirco Cosottini, Eleonora Del Prete, Sonia Mazzucchi, Aldo Quattrone

Summary: The measurement of third ventricle width can distinguish Parkinson's disease (PD) from progressive supranuclear palsy (PSP).

MOVEMENT DISORDERS (2021)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.